Pinilla-Ibarz J - Search Results

1

Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.

Jain AG, Gesiotto Q, Ball S, Nodzon L, Rodriguez A, Chan O, Padron E, Kuykendall A, Komrokji R, Sallman DA, Lancet JE, Pinilla-Ibarz J, Sweet K. Jain AG, et al. Among authors: pinilla ibarz j. Ann Hematol. 2024 Jun;103(6):1941-1945. doi: 10.1007/s00277-024-05760-6. Epub 2024 Apr 18. Ann Hematol. 2024. PMID: 38634915 Free PMC article.

2

The one-two punch: combination treatment in chronic myeloid leukemia.

Sweet KL, Hazlehurst LA, Pinilla-Ibarz J. Sweet KL, et al. Crit Rev Oncol Hematol. 2013 Dec;88(3):667-79. doi: 10.1016/j.critrevonc.2013.07.017. Epub 2013 Aug 20. Crit Rev Oncol Hematol. 2013. PMID: 23969231 Review.

3

Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations.

Sweet K, Pinilla-Ibarz J, Zhang L. Sweet K, et al. Patient Prefer Adherence. 2014 Jul 8;8:981-6. doi: 10.2147/PPA.S53160. eCollection 2014. Patient Prefer Adherence. 2014. PMID: 25045255 Free PMC article. Review.

4

Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia.

Sweet K, Al Ali NH, Dalia SM, Komrokji RS, Crescentini RM, Tinsley S, Lancet JE, Papenhausen PR, Zhang L, Pinilla-Ibarz J. Sweet K, et al. Int J Hematol. 2014 Dec;100(6):567-74. doi: 10.1007/s12185-014-1685-9. Epub 2014 Oct 4. Int J Hematol. 2014. PMID: 25281405

5

WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.

Brayer J, Lancet JE, Powers J, List A, Balducci L, Komrokji R, Pinilla-Ibarz J. Brayer J, et al. Am J Hematol. 2015 Jul;90(7):602-7. doi: 10.1002/ajh.24014. Epub 2015 May 3. Am J Hematol. 2015. PMID: 25802083 Free PMC article. Clinical Trial.

6

Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: An emerging clinical question.

Sweet K, Pinilla-Ibarz J. Sweet K, et al. Crit Rev Oncol Hematol. 2016 Jul;103:99-108. doi: 10.1016/j.critrevonc.2016.05.009. Epub 2016 May 14. Crit Rev Oncol Hematol. 2016. PMID: 27262540 Review.

7

NCCN and ELN: What do the guidelines tell us?

Sweet K, Pinilla-Ibarz J. Sweet K, et al. Best Pract Res Clin Haematol. 2016 Sep;29(3):264-270. doi: 10.1016/j.beha.2016.10.016. Epub 2016 Oct 20. Best Pract Res Clin Haematol. 2016. PMID: 27839567 Review.

8

Can increased immunogenicity in chronic myeloid leukemia improve outcomes?

Chan O, Talati C, Sweet K, Pinilla-Ibarz J. Chan O, et al. Expert Rev Hematol. 2019 Apr;12(4):225-233. doi: 10.1080/17474086.2019.1588105. Epub 2019 Mar 11. Expert Rev Hematol. 2019. PMID: 30855193 Review.

9

Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes.

Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF. Komrokji RS, et al. Am J Hematol. 2012 Nov;87(11):1006-9. doi: 10.1002/ajh.23303. Epub 2012 Aug 1. Am J Hematol. 2012. PMID: 23090887 Free article.

10

Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.

Mishra A, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF, Komrokji RS. Mishra A, et al. Am J Hematol. 2013 Jul;88(7):566-70. doi: 10.1002/ajh.23454. Epub 2013 May 30. Am J Hematol. 2013. PMID: 23605934 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

174 results

Search Page